Drug Profile
Testosterone and anastrozole subcutaneous pellet - Havah Therapeutics
Alternative Names: CLAR-121; HAVAH T+Ai™; T+Ai™Latest Information Update: 20 May 2022
Price :
$50
*
At a glance
- Originator HAVAH Therapeutics
- Developer Clarus Therapeutics; HAVAH Therapeutics
- Class Anabolic steroids; Antineoplastics; Erectile dysfunction therapies; Eye disorder therapies; Nitriles; Small molecules; Triazoles
- Mechanism of Action Aromatase inhibitors; Testosterone agonists; Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast disorders
- No development reported Breast cancer
Most Recent Events
- 16 May 2022 Clarus Therapeutics applies for Orphan Drug Designation from the US FDA for the treatment of inflammatory periductal mastitis
- 10 May 2022 Clarus Therapeutics announces intention to request for orphan drug designation to the US FDA in Q2 of 2022
- 10 May 2022 Clarus Therapeutics receives notice of allowance from USPTO for testosterone and anastrozole subcutaneous pellet in USA